Table 2. Systemic hemodynamic parameters.

	Solv.	12 µM	100 µM	∑ NS1619	Solv. vs.∑ NS1619	Solvent	12 µM	100 µM	∑ NS1619	Solv. vs.∑ NS1619
heart rate (bpm)	−0,9±8,6	−19,2±17,3	+6,9±6,7	−6,2±9,6	P = 0,70	+4,2±6,7	+5,6±11,1	−9,5±13,7	−1,9±8,7	P = 0,61
bp sys (mmHg)	−2,2±5,1	−4,7±5,9	+0,9±5,6	−1,9±4,0	P = 0,96	−0,0±10,0	−5,1±7,1	−1,7±9,1	−3,4±5,6	P = 0,75
bp mean (mmHg)	+0,6±2,7	+0,0±4,0	+3,2±4,1	+1,6±2,8	P = 0,79	+2,3±8,8	−0,4±6,6	+1,0±9,2	+0,3±5,5	P = 0,84
bp dia (mmHg)	+0,7±2,7	+0,7±3,6	+3,7±3,2	+2,2±2,4	P = 0,68	+2,0±8,9	+2,0±6,3	+2,2±7,9	+2,1±4,8	P = 0,99
	(Δ) 30 min after inhalation					(Δ) 120 min after inhalation

Heart rate, systolic (bp sys), mean (bp mean), diastolic (bp dia) arterial blood pressure were determined before (basis) as well as 30 and 120 minutes after inhalation of two different NS1619 concentrations, respectively solvent. Data obtained after inhalation were subtracted from individual basis values and individual value differences (Δ) were calculated for each animal and time point. None of the parameters investigated were affected by NS1619 inhalation in a significant manner. According to the character of the study as “a proof of principle”, pooled NS1619 (∑NS1619) data was compared with the control group (Solvent = Solv.). No NS1619-dependent effect on systemic hemodynamic parameters was discovered.